Finally, it's important to look at SinoVac as a successful company – well beyond Covid. The company had $440 million in sales in 2023, and $121 million in in the first half of 2024 (the business is highly seasonal and financials for the second half of 2024 have not yet been filed), with revenue coming from a variety of non-covid drugs and geographies. While the company's cash value may be around $140 per share, the real job of the new board is to focus on getting the company focused on its operations – rather than fights and lawsuits. After so many years, investors who vote for board change may finally reap the rewards of SinoVac's underlying success.